Filtered By:
Source: Journal of the American College of Cardiology
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 269 results found since Jan 2013.
Impact of Low Flow on the Outcome of High-Risk Patients Undergoing Transcatheter Aortic Valve Replacement
This study sought to assess the impact of baseline left ventricular (LV) outflow, LV ejection fraction (LVEF), and transvalvular gradient on outcomes following transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis (AS).Background: Low flow (i.e., reduced stroke volume index [SVi]) can occur with both reduced and preserved LVEF. Low flow is often associated with low gradient despite severe stenosis and with worse outcomes following surgical aortic valve replacement. However, there are few data about the impact of low flow on outcomes following TAVR.Methods: We retrospectively analyzed the cli...
Source: Journal of the American College of Cardiology - June 14, 2013 Category: Cardiology Authors: Florent Le Ven, Mélanie Freeman, John Webb, Marie-Annick Clavel, Miriam Wheeler, Éric Dumont, Chris Thompson, Robert De Larochellière, Robert Moss, Daniel Doyle, Henrique B. Ribeiro, Marina Urena, Luis Nombela-Franco, Josep Rodés-Cabau, Philippe Pibar Tags: Transcatheter Aortic Valve Replacement Source Type: research
Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation
Conclusions: On a group level both doses of dabigatran as compared with warfarin have similar benefits when considering a weighted estimate including both efficacy and safety. The similar overall benefits of the 2 doses of dabigatran versus warfarin support individualizing the dose based on patient characteristics and physician and patient preferences. (Randomized Evaluation of Long Term Anticoagulant Therapy [RE-LY] With Dabigatran Etexilate; NCT00262600)
Source: Journal of the American College of Cardiology - June 14, 2013 Category: Cardiology Authors: John W. Eikelboom, Stuart J. Connolly, Robert G. Hart, Lars Wallentin, Paul Reilly, Jonas Oldgren, Sean Yang, Salim Yusuf Tags: Heart Rhythm Disorders Source Type: research
The ATLAS ACS 2–TIMI 51 Trial and the Burden of Missing Data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2–Thrombolysis In Myocardial Infarction 51)
Rivaroxaban is a factor Xa inhibitor that was recently reviewed by the Food and Drug Administration as a potential therapy to reduce the risk of recurrent atherothrombotic events in patients with acute coronary syndromes. Approval of this drug would represent a paradigm shift away from dual antiplatelet therapy toward long-term triple antithrombotic therapy. However, to date, no other experimental anticoagulant agent has demonstrated a favorable risk-benefit profile in this population, in part because of the expected increased risk in major bleeding by combining aspirin, a P2Y12 receptor inhibitor, and an anticoagulant. Ap...
Source: Journal of the American College of Cardiology - June 10, 2013 Category: Cardiology Authors: Mori J. Krantz, Sanjay Kaul Tags: VIEWPOINT Source Type: research
Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention
Conclusions: In real-life AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel was equal or better on both benefit and safety outcomes compared to triple therapy.
Source: Journal of the American College of Cardiology - June 10, 2013 Category: Cardiology Authors: Morten Lamberts, Gunnar H. Gislason, Jonas Bjerring Olesen, Søren Lund Kristensen, Anne-Marie Schjerning Olsen, Anders Mikkelsen, Christine Benn Christensen, Gregory Y.H. Lip, Lars Køber, Christian Torp-Pedersen, Morten Lock Hansen Tags: Coronary Artery Disease Source Type: research
Antithrombotic Regimens in Patients With Atrial Fibrillation and Coronary Disease: Optimizing Efficacy and Safety∗
Clear evidence supports the value of oral anticoagulation (OAC) with vitamin K antagonists in preventing stroke and thromboembolism in patients with atrial fibrillation (AF) who have well-established risk factors. For this indication, vitamin K antagonists have been shown to be superior to single or dual antiplatelet agents in reducing thromboembolic complications . Yet, up to 30% of patients with AF also have indications for antiplatelet therapy because of coronary artery disease . Dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor (e.g., clopidogrel) is usually recommended after stent implantation or a...
Source: Journal of the American College of Cardiology - June 10, 2013 Category: Cardiology Authors: Steven M. Markowitz Tags: Coronary Artery Disease: Editorial Comment Source Type: research
In Vivo Evaluation of Atherosclerotic Plaque Inflammation and of Anti-Inflammatory Effects of Statins by 18F-Fluorodeoxyglucose Positron Emission Tomography∗
Atherosclerosis is currently no longer considered merely a cholesterol storage disease, but rather a complex process of vascular inflammation . Indeed, various inflammatory cells and, in particular, monocytes and macrophages play a major role in the development, progression, and rupture of atherosclerotic plaques . Atherosclerosis is initiated when blood monocytes and T lymphocytes are attracted by chemokinesis to oxidized apo-B rich lipoproteins in the vessel wall. Expression of vascular cell adhesion molecule-1 and E- and P-selectin by the endothelium allows their adherence and entry into the subendothelial space. Monocy...
Source: Journal of the American College of Cardiology - June 3, 2013 Category: Cardiology Authors: Bernhard L. Gerber Tags: Cardiac Imaging: Editorial Comment Source Type: research
Stroke, Superior Vena Cava Syndrome, and the Snowman in the Chest Roentgenogram
A 55-year-old man had left hemiparesis 1 month earlier, followed by progressive swelling and dilated nonpulsatile veins over the chest, neck, and upper arm (A, arrows) along with a pulsatile swelling over the right infraclavicular and parasternal area. A chest x-ray (B) showed a widened superior mediastinum with a “figure of 8” appearance. Transthoracic echocardiogram showed a dilated left ventricle (LV) with severe aortic regurgitation (G, Online Video 1). The ascending aorta (AA) was aneurysmally dilated, with a mobile thrombus (asterisk) attached to its wall (E, Online Video 2). Bicaval view (F, Online Video 3) sho...
Source: Journal of the American College of Cardiology - May 28, 2013 Category: Cardiology Authors: Bhupinder Singh, Ravindran Rajendran, Yadvinder Singh, Vivek Singla, Ravindranath K. Shankarappa, Manjunath C. Nanjappa Tags: IMAGES IN CARDIOLOGY Source Type: research
Brief Episodes of Silent Atrial Fibrillation Predict Clinical Vascular Brain Disease in Type 2 Diabetic Patients
This study evaluated whether subclinical episodes of atrial fibrillation (AF) were associated with an increased risk of silent cerebral infarct (SCI) and stroke in diabetic patients younger than 60 years who did not have other clinical evidence of AF and cerebrovascular disease at baseline.Background: In type 2 diabetic patients, one-fourth of strokes are of unknown cause, and subclinical episodes of AF may be a common etiologic factor.Methods: A total of 464 type 2 diabetic patients younger than 60 years were included in a longitudinal observational study and matched to patients without diabetes. Patients underwent 48-h e...
Source: Journal of the American College of Cardiology - May 17, 2013 Category: Cardiology Authors: Raffaele Marfella, Ferdinando Carlo Sasso, Mario Siniscalchi, Mario Cirillo, Pasquale Paolisso, Celestino Sardu, Michelangela Barbieri, Maria Rosaria Rizzo, Ciro Mauro, Giuseppe Paolisso Tags: Heart Rhythm Disorders Source Type: research
Subtle Post-Procedural Cognitive Dysfunction After Atrial Fibrillation Ablation
Conclusions: Ablation for AF is associated with a 13% to 20% prevalence of POCD in patients with AF at long-term follow-up. These results were seen in a patient population with predominant CHADS2 (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke/transient ischemic attack) scores of 0 to 1, representing the majority of patients undergoing ablation for AF. The long-term implications of these subtle changes require further study.
Source: Journal of the American College of Cardiology - May 17, 2013 Category: Cardiology Authors: Caroline Medi, Lisbeth Evered, Brendan Silbert, Andrew Teh, Karen Halloran, Joseph Morton, Peter Kistler, Jonathan Kalman Tags: Heart Rhythm Disorders Source Type: research
Preserve the Brain: Primary Goal in the Therapy of Atrial Fibrillation∗
Treatment of atrial fibrillation (AF) involves 3 major strategies: prevention of stroke, maintenance of sinus rhythm, and rate control . Stroke is the most dreaded complication of AF, and its prevention is key. Anticoagulation with warfarin and the newer agents dabigatran, rivaroxaban, and apixaban is highly effective in preventing strokes in patients with AF . However, defining the appropriate patient for anticoagulant therapy is not an exact science, and the stroke risk schema CHADS2 (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke/transient ischemic attack) and CHA2DS2-VASc (...
Source: Journal of the American College of Cardiology - May 17, 2013 Category: Cardiology Authors: Eric N. Prystowsky, Benzy J. Padanilam Tags: Heart Rhythm Disorders: Editorial Comment Source Type: research
Percutaneous Left Atrial Appendage Closure With the AMPLATZER Cardiac Plug Device in Patients With Nonvalvular Atrial Fibrillation and Contraindications to Anticoagulation Therapy
Conclusions: In patients with nonvalvular atrial fibrillation at high risk of cardioembolic events and absolute contraindications to anticoagulation, LAAC using the ACP device followed by dual-/single-antiplatelet therapy was associated with a low rate of embolic and bleeding events after a mean follow-up of 20 months. No cases of severe residual leak or device thrombosis were observed at the 6-month follow-up.
Source: Journal of the American College of Cardiology - May 13, 2013 Category: Cardiology Authors: Marina Urena, Josep Rodés-Cabau, Xavier Freixa, Jacqueline Saw, John G. Webb, Mélanie Freeman, Eric Horlick, Mark Osten, Albert Chan, Jean-Francois Marquis, Jean Champagne, Réda Ibrahim Tags: Mini-Focus: Left Atrial Closure in Atrial Fibrillation Source Type: research
The Assault on the Left Atrial Appendage in Perspective∗
For patients with atrial fibrillation (AF) inappropriate for or refractory to ablation or cardioversion, the choices have been austere: treat with anticoagulation or expose the patient to a 5-fold or greater risk of embolic events including stroke. Anticoagulation remains the standard of care and has been studied extensively in multiple level I trials, most recently as part of the introduction of a new-generation polypharmacy for nonvalvular AF. Anticoagulation nevertheless remains an iatrogenically induced disease with significant associated morbidity and mortality to which patients may be exposed for decades. Mechanical ...
Source: Journal of the American College of Cardiology - May 13, 2013 Category: Cardiology Authors: Zoltan G. Turi Tags: Mini-Focus: Left Atrial Closure in Atrial Fibrillation: Editorial Comment Source Type: research
Good Fat, Bad Fat: The Increasingly Complex Interplay of Adipose Tissue and the Cardiovascular System∗
Obesity is present in more than 30% of adults in the United States and is a known risk factor for a variety of cardiovascular problems, including coronary artery disease, atrial fibrillation, congestive heart failure, and stroke . Obesity is considered to be present when there is an excess mass of adipose tissue in the body. There is now widespread acceptance of the notion that regional fat stores might have specific local or systemic effects. The best-known example of a local fat depot with a specific effect is the case of excess fat within the abdominal cavity, which seems to contribute to insulin resistance, raised bloo...
Source: Journal of the American College of Cardiology - May 13, 2013 Category: Cardiology Authors: Sheldon E. Litwin Tags: Cardiometabolic Risk: Editorial Comment Source Type: research
Patent Foramen Ovale, Subclinical Cerebrovascular Disease, and Ischemic Stroke in a Population-Based Cohort
Conclusions: In this community-based cohort, PFO was not associated with an increased risk of clinical stroke or subclinical cerebrovascular disease.
Source: Journal of the American College of Cardiology - May 3, 2013 Category: Cardiology Authors: Marco R. Di Tullio, Zhezhen Jin, Cesare Russo, Mitchell S.V. Elkind, Tatjana Rundek, Mitsuhiro Yoshita, Charles DeCarli, Clinton B. Wright, Shunichi Homma, Ralph L. Sacco Tags: Patent Foramen Ovale and Stroke Source Type: research
Patent Foramen Ovale Science: Keeping the Horse in Front of the Cart∗
Compared with a prevalence of 25% in the general population, the higher prevalence of patent foramen ovale (PFO) in cryptogenic stroke (CS) patients has led to the intuitive conclusion that PFO is a risk factor for CS . However, distinguishing truly culpable PFOs from the innocent bystanders has been difficult. Some have advocated closure for just about any PFO , an approach which subjects people (many are not yet “patients” with any PFO-related neurological or other clinical syndrome) to procedural and device-related risks. This clearly puts the cart before the horse. PFO closure for secondary stroke prevention contin...
Source: Journal of the American College of Cardiology - May 3, 2013 Category: Cardiology Authors: Deeb N. Salem, David E. Thaler Tags: Patent Foramen Ovale and Stroke: Editorial Comment Source Type: research
